Compare AUDC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AUDC | ENGN |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.7M | 117.2M |
| IPO Year | 2000 | 2023 |
| Metric | AUDC | ENGN |
|---|---|---|
| Price | $10.07 | $1.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.50 | ★ $21.08 |
| AVG Volume (30 Days) | 84.7K | ★ 655.9K |
| Earning Date | 05-05-2026 | 06-11-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $1.40 |
| 52 Week High | $10.86 | $12.25 |
| Indicator | AUDC | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 54.93 |
| Support Level | $8.82 | $1.67 |
| Resistance Level | $10.31 | $1.95 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 67.56 | 77.78 |
AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.